Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.
about
Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogsRole of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motilityGammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in miceGene knockdown by large circular antisense for high-throughput functional genomics.Chemical modification: the key to clinical application of RNA interference?Identification of genes involved in liver cancer cell growth using an antisense library of phage genomic DNA.Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.Maternal HtrA3 optimizes placental development to influence offspring birth weight and subsequent white fat gain in adulthood.Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.Therapeutic RNA manipulation in liver disease.Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs.Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.Direct cloning, genetic engineering, and heterologous expression of the syringolin biosynthetic gene cluster in E. coli through Red/ET recombineering.Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BSpecific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease.Activation of presynaptic NMDA receptors coupled to NaV1.8-resistant sodium channel C-fibers causes retrograde mechanical nociceptor sensitization.Antisense oligonucleotide therapy for neurodegenerative disease.Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes.Effects of minocycline on Fas-mediated fulminant hepatitis in miceThe distribution pattern of DNA and protoxin in Bacillus thuringiensis as revealed by laser confocal microscopy analysis.Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis.Genetic engineering and heterologous expression of the disorazol biosynthetic gene cluster via Red/ET recombineering.Room temperature electrocompetent bacterial cells improve DNA transformation and recombineering efficiency.IVA cloning: A single-tube universal cloning system exploiting bacterial In Vivo AssemblyModulation of apoptosis as a target for liver disease.Idiosyncratic drug hepatotoxicity.Glucagon as a target for the treatment of Type 2 diabetes.In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.Antisense oligonucleotides as therapeutics for hyperlipidaemias.Intracellular signaling mechanisms of acetaminophen-induced liver cell death.Role of innate immunity in acetaminophen-induced hepatotoxicity.Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity.Cellular and molecular mechanisms of liver injury.Fas receptor-deficient lpr mice are protected against acetaminophen hepatotoxicity due to higher glutathione synthesis and enhanced detoxification of oxidant stress.Bioconjugation of oligonucleotides for treating liver fibrosis.The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity.Simple and rapid direct cloning and heterologous expression of natural product biosynthetic gene cluster in Bacillus subtilis via Red/ET recombineering.Apoptosis and necrosis in the liver
P2860
Q24555118-496132DB-E5CF-44A0-A61A-40F4F50A4F5BQ28214662-6DC7642C-353B-4303-831D-31F5BED58762Q30439944-C5B61CC8-E54D-497B-A8D8-93B09E2F244DQ30495814-0723FC8E-447A-4CA1-BD4E-3E20779589B4Q31168008-5409D7E7-27CE-4054-B5F7-6F40FBD91831Q33308712-15B72678-5EE1-483B-90C8-2661062FB327Q33549658-FBE80EE6-07AC-4EC9-9563-26EC3F6D3472Q33695961-6CBF4129-9620-41D4-83C1-B1A62A863D3EQ33870606-7EBF92E4-C7AB-424C-BFA4-84BD9BC11B70Q34169410-E1E5CA2A-8416-44CA-8ED3-B053D608E1C5Q34240839-B8E6CE64-1C9D-42BD-8152-ED4D6FE70F2CQ34244756-3C854112-E83C-4B6C-872E-CFD69E7ED143Q34298362-A80FF6AC-2E04-459D-BFF9-A1E12E562BA8Q34328200-1E127371-B41A-415E-A9E9-2FBE24B9FE1AQ34360740-9AA6FBDA-9B51-497F-8D88-AD789C0F1D1CQ34456562-5D79B53F-EDDD-4154-9CBD-9114BF602F3AQ34654019-2CCC5E83-F0FC-45A3-9803-BD046F4AFCC9Q34809091-44B62B77-1F2E-4101-B544-1E361C9D2785Q34830633-1037B3F1-B338-4B43-9387-0A89B0DFFE52Q35041004-866CF1C4-480F-436B-90AD-74D512B50475Q35048549-039CB7A5-A40B-4BBB-803C-2BB6F3D91006Q35567792-E1F4973D-278F-4807-9321-2BB95DB429E2Q35817615-10BE15B7-1F9A-4DC2-AAA8-1905FECD3F39Q35923366-976677A4-2AA6-4B85-BEAB-DAFA4B0B551AQ35994397-9D4D9665-8ABA-4F12-BCAE-A99ADA0CBC79Q36041542-DE9CE397-2153-432F-882B-C95477A97D97Q36066290-D9793029-C17E-4E3B-B507-C79789418CB1Q36148442-4D59936D-514F-4339-9E78-C73D122F81B8Q36158732-1BEF9270-1BDE-4433-BB64-9502DF4EA741Q36160667-9BE20708-2322-4AE1-971C-0A8AC8C757D8Q36194069-5F96AE9A-7515-4150-91BF-15D1874ED84EQ36263962-C01855E8-56F4-48D5-8449-7C748692B071Q36543087-BC2139D8-2A15-40E9-A61D-31E3D942873FQ36652448-E2B6912B-DBC5-4D36-B9BC-8127F9FF789FQ36908855-4528FDF7-A5DA-4497-A615-177E727B29F6Q36988910-34BEED92-E31A-4B89-A389-8B87D4B1E659Q37043515-03C8745B-4021-4E16-9EC7-3454D4754350Q37137513-4EE1AB04-FE06-4DD3-9AC3-3A87AAB3AE84Q37298814-47B16BF4-7E06-47E4-85A5-57286ED1ED56Q37403072-1DA7CB0C-B8D3-4A00-93D5-25752EBF120D
P2860
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@en
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@nl
type
label
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@en
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@nl
prefLabel
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@en
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@nl
P2093
P2860
P356
P1433
P1476
Reduction of liver Fas express ...... mice from fulminant hepatitis.
@en
P2093
P2860
P2888
P304
P356
10.1038/78475
P577
2000-08-01T00:00:00Z
P6179
1012419864